Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban vs VKA on Cardiovascular Calcification in AF/PE
NCT02066662Phase 4Completed
- Sponsor
- RWTH Aachen University
- Start
- Jul 2013
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rivaroxaban in Atrial fibrillation (AFib) and pulmonary embolism (PE) (2 arms), sponsored by RWTH Aachen University. Primary endpoint: Progression of coronary and aortic valve calcification at 24 months. Started Jul 2013; status: completed.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT02066662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02066662.